Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients

    Suyog Sindhu1★, Hemant Kumar Singh1, Mohammad Tariq Salman1, Jalees Fatima2, Vinod Kumar Verma1★ Corresponding author

    1. 1Departments of Pharmacology, College and Hospital, Lucknow, Uttar Pradesh, India Research Paper.
    2. 2Medicine, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India Research Paper.

    CORRESPONDENCE

    Suyog Sindhu

    Departments of Pharmacology, College and Hospital, Lucknow, Uttar Pradesh, India Research Paper.

    Volume 2, Issue 4 · pp. 261–265 · PUBLISHED 2011 · DOI: 10.4103/0976-500X.85954

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Objective: To evaluate and compare the effects on high-sensitivity C-reactive protein (hs-CRP) levels and lipid profi le of atorvastatin and rosuvastatin in obese type 2 diabetes mellitus (T2DM) patients. Materials and Methods: A total of 40 subjects with 20 in each group were randomly allocated to two groups. Group 1 patients received atorvastatin and that of Group 2 rosuvastatin treatment for 6 months. The patients were administered atorvastatin (40-80 mg) and rosuvastatin(10-40 mg) in accordance to their LDL-C status as per NCEP-ATP III guidelines. The parameters studied were, hs-CRP and lipid profi le comprising LDL-C, HDL-C, TG and TC. Results: Results obtained from the study, clearly indicate that atorvastatin (A) as well as rosuvastatin(R) have signifi cant effect on lowering of hs-CRP levels (for A P=0.001; for R P=0.002), reducing LDL-C levels (for A P=0.008; for R P=0.001), elevating HDL-C levels (for A P=0.02; for R P=0.001) along with reducing TC (for A P=0.003; for R P=0.002) and TG (for A P=0.000; for R P=0.000) levels in obese T2DM patients. It is also seen that there is no signifi cant (P>0.05) difference in effect of atorvastatin and rosuvastatin in lowering of hs-CRP levels, elevating HDL-C levels and reducing TG levels in obese T2DM patients. However, percentage lowering of LDL-C (P=0.000) and TC (P=0.001) by rosuvastatin is to a greater extent than that caused by atorvastatin in these patients. Conclusions: Thus this study throws light on the fact that rosuvastatin should be preferred over atorvastatin in obese T2DM patients in whom LDL-C and TC levels are deviated from normal reference values. In rest of obese T2DM either of atorvastatin or rosuvastatin can be employed to lower hs-CRP levels, to elevate HDL-C levels or to reduce TG levels.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Sindhu, S., Singh, H. K., Salman, M. T., Fatima, J., & Verma, V. K. (2011). Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. Journal of Pharmacology and Pharmacotherapeutics, 2(4), 261–265. https://doi.org/10.4103/0976-500X.85954